Delcath Systems (NASDAQ: DCTH) is a specialty pharmaceutical and medical device company focused on oncology and the treatment of primary and metastatic liver cancers. The company’s proprietary Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. The company’s second-generation system is currently marketed in Europe as a device as Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In the U.S., the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the U.S. Food and Drug Administration (FDA). Melphalan/HDS has not been approved for sale in the U.S. For more information, visit the company’s website at www.delcath.com